Key statistics
As of last trade Emergent BioSolutions Inc (EBS:NYQ) traded at 9.53, -36.89% below its 52-week high of 15.10, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.40 |
---|---|
High | 9.67 |
Low | 9.37 |
Bid | 9.53 |
Offer | 9.55 |
Previous close | 9.40 |
Average volume | 1.78m |
---|---|
Shares outstanding | 54.18m |
Free float | 53.05m |
P/E (TTM) | -- |
Market cap | 509.33m USD |
EPS (TTM) | -4.10 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:23 GMT.
More ▼
- Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
- Emergent BioSolutions Reports Third Quarter 2024 Financial Results
- Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
- Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
- Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
- Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
- Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
- Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
- Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
More ▼